ImmuCell (NASDAQ:ICCC) announced its earnings results on Monday. The biotechnology company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.07, MarketWatch Earnings reports. ImmuCell had a negative net margin of 9.99% and a negative return on equity of 5.32%. ImmuCell updated its Q1 2021
After-Hours guidance to EPS.
Shares of ICCC traded down $1.68 during trading hours on Tuesday, hitting $10.06. The company had a trading volume of 692 shares, compared to its average volume of 73,251. The firm has a fifty day moving average price of $8.64 and a 200-day moving average price of $6.42. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.35 and a current ratio of 5.51. The stock has a market capitalization of $72.56 million, a price-to-earnings ratio of -45.65 and a beta of 1.14. ImmuCell has a 52-week low of $3.70 and a 52-week high of $13.20.
ICCC has been the topic of a number of recent analyst reports. Aegis reaffirmed a “buy” rating on shares of ImmuCell in a research note on Monday, February 15th. TheStreet raised shares of ImmuCell from a “d+” rating to a “c-” rating in a research note on Tuesday, December 8th.
ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
Further Reading: How to Invest in a Bull Market
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.